Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VIII: structure and function in blood clotting.

S I Chavin

    American Journal of Hematology
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Factor VIII (antihemophilic factor) is crucial for blood clotting and is deficient in hemophilia. Research aims to understand its complex role and improve treatments for inherited clotting disorders.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preventive medicine and screening in older adults.

    Journal of the American Geriatrics Society·1997
    Same author

    Erythropoietin therapy for anemia.

    Journal of the American Geriatrics Society·1995
    Same author

    Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor.

    The American journal of medicine·1988
    Same author

    Inactivation of factor VIII by activated protein C and protein S.

    Archives of biochemistry and biophysics·1987
    Same author

    The size of human factor VIII heterodimers and the effects produced by thrombin.

    Biochimica et biophysica acta·1986
    Same author

    Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II.

    Science (New York, N.Y.)·1986
    Same journal

    Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait.

    American journal of hematology·2026
    Same journal

    POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.

    American journal of hematology·2026
    Same journal

    EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

    American journal of hematology·2026
    Same journal

    Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

    American journal of hematology·2026
    Same journal

    High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

    American journal of hematology·2026
    Same journal

    Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

    American journal of hematology·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Hematology
    • Molecular Biology

    Background:

    • Factor VIII (antihemophilic factor) is essential for normal blood coagulation.
    • Deficiency or defects in Factor VIII cause classical hemophilia and Von Willebrand syndrome.
    • Factor VIII circulates in plasma associated with Von Willebrand protein multimers.

    Purpose of the Study:

    • To elucidate the biochemical properties and function of Factor VIII in blood clotting.
    • To investigate the activation and inactivation mechanisms of Factor VIII.
    • To explore the potential for improved clinical applications for Factor VIII-related bleeding disorders.

    Main Methods:

    • Purification of human Factor VIII.
    • Characterization of Factor VIII molecular weight and polypeptide composition.

    Related Experiment Videos

  • Assays to evaluate Factor VIII activity, activation, and inactivation by various proteases.

    • Main Results:

    • Purified Factor VIII (200-300 kDa) comprises multiple polypeptide chains.
    • Factor VIII accelerates Factor X activation by Factor IXa, forming a functional complex.
    • Factor VIII is activated by thrombin, Factor Xa, and inactivated by thrombin and activated protein C.

    Conclusions:

    • Factor VIII plays a critical, non-enzymatic role in the coagulation cascade.
    • Proteolytic cleavage, particularly by thrombin, significantly modulates Factor VIII activity.
    • Further research into Factor VIII mechanisms is vital for treating inherited bleeding disorders.